Literature DB >> 29350392

Diagnostic and prognostic micro-RNAs in ischaemic stroke due to carotid artery stenosis and in acute coronary syndrome: a four-year prospective study.

Jacek Gacoń, Rafał Badacz, Ewa Stępień, Izabela Karch, Francisco J Enguita, Krzysztof Żmudka, Tadeusz Przewłocki, Anna Kabłak-Ziembicka1.   

Abstract

BACKGROUND: Circulating microRNAs (miRs) levels are potentially important diagnostic and prognostic biomarkers in acute coronary syndrome (ACS) or cerebral ischaemic events (CIE) resulting from internal carotid artery stenosis (ICAS). AIM: This four-year prospective study aimed to compare the levels of circulating miRs in ACS vs. CIE patients, and investigate miRs potentially associated with risk of recurrent cardiovascular events.
METHODS: The circulating miRs levels (miR-1-3p, miR-16-5p, miR-34a-5p, mir-122-5p, miR-124-3p, miR-133a-3p, miR-133b, miR-134-5p, miR-208b-3p, miR-375, and miR-499-5p) were compared in 43 (34 men, 57.6 ± 10.1 years) patients with ACS, and in 71 (47 men, 69.5 ± 9.6 years) with CIE due to ICAS. A four-year prospective evaluation of miRs associated with risk of cardiovascular death (CVD), myocardial infarction (MI), CIE, or all (CVD/MI/CIE) was performed.
RESULTS: In ACS vs. CIE patients, the levels of miR-124-3p (p < 0.001), miR-134-5p (p = 0.012), miR-208b-3p (p < 0.001), miR-34a-5p (p < 0.001), and miR-499-5p (p < 0.001) were higher, while levels of miR-16-5p (p < 0.001) and miR-122-5p (p < 0.001) were lower. Levels of miR-1-3p (p = 0.195), miR-133a-3p (p = 0.333), miR-133b (p = 0.056), and miR-375 (p = 0.055) were non-statistically different. During follow-up (median 57 months, Q1-Q3: 54-60), CVD/MI/CIE occurred in 23 subjects, including eight CVDs, five non-fatal CIEs, and 10 non-fatal MIs. The multivariate Cox proportional hazard analysis (relative risk [RR]; 95% confidence interval [CI]) revealed that miR-208b-3p (1.225; 1.092-1.375), miR-34a-5p (0.963; 0.935-0.992), and miR-499-5p (0.077; 0.025-0.239) were independently associated with risk of CVD/MI/CIE, as well as risk of each event. Furthermore, miR-133b (1.009; 1.003-1.015) was associated with risk of CVD.
CONCLUSIONS: This study shows that although most investigated miRs levels differ significantly between patients with ACS and CIE, similar levels of circulating miR-1-3p, miR-133a-3p, miR-133b, and miR-375 were observed; furthermore, we identified several common miRs as possible risk factors for recurrent cardiovascular events.

Entities:  

Keywords:  acute coronary syndrome; cerebral ischaemic event; circulating miRs; prognostic miRs

Mesh:

Substances:

Year:  2018        PMID: 29350392     DOI: 10.5603/KP.a2017.0243

Source DB:  PubMed          Journal:  Kardiol Pol        ISSN: 0022-9032            Impact factor:   3.108


  13 in total

1.  Longitudinal change in microRNA-130a expression and its correlation with the risk of developing major adverse cardiovascular and cerebral events in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  Hong Wang; Jinglin Xu; Xinhong Wu; Shouhao Zheng; Yingmin Han; Guoming Ding
Journal:  J Clin Lab Anal       Date:  2021-10-28       Impact factor: 2.352

2.  Substantially Altered Expression Profile of Diabetes/Cardiovascular/Cerebrovascular Disease Associated microRNAs in Children Descending from Pregnancy Complicated by Gestational Diabetes Mellitus-One of Several Possible Reasons for an Increased Cardiovascular Risk.

Authors:  Ilona Hromadnikova; Katerina Kotlabova; Lenka Dvorakova; Ladislav Krofta; Jan Sirc
Journal:  Cells       Date:  2020-06-26       Impact factor: 6.600

3.  Effect of radiotherapy on the expression of cardiovascular disease-related miRNA-146a, -155, -221 and -222 in blood of women with breast cancer.

Authors:  Roser Esplugas; Meritxell Arenas; Noemí Serra; Montserrat Bellés; Marta Bonet; Marina Gascón; Joan-Carles Vallvé; Victoria Linares
Journal:  PLoS One       Date:  2019-05-31       Impact factor: 3.240

4.  The role of serial carotid intima-media thickness assessment as a surrogate marker of atherosclerosis control in patients with recent myocardial infarction.

Authors:  Jacek Gacoń; Tadeusz Przewlocki; Jakub Podolec; Rafal Badacz; Piotr Pieniazek; Wojciech Ryniewicz; Krzysztof Żmudka; Anna Kabłak-Ziembicka
Journal:  Postepy Kardiol Interwencyjnej       Date:  2019-03-04       Impact factor: 1.426

5.  Plasma exosome-derived microRNAs expression profiling and bioinformatics analysis under cross-talk between increased low-density lipoprotein cholesterol level and ATP-sensitive potassium channels variant rs1799858.

Authors:  Cheng Liu; Yanxian Lai; Songsong Ying; Junfang Zhan; Yan Shen
Journal:  J Transl Med       Date:  2020-12-03       Impact factor: 5.531

6.  Expression and Clinical Value of miR-185 and miR-424 in Patients with Acute Ischemic Stroke.

Authors:  Chunxuan Guo; Yanping Yao; Qi Li; Yuanjie Gao; Hongyan Cao
Journal:  Int J Gen Med       Date:  2022-01-04

7.  Anti-inflammatory effects of artesunate on atherosclerosis via miR-16-5p and TXNIP regulation of the NLRP3 inflammasome.

Authors:  Bo Li; Zheqi Zhang; Yili Fu
Journal:  Ann Transl Med       Date:  2021-10

8.  miR-124-3p targeted SIRT1 to regulate cell apoptosis, inflammatory response, and oxidative stress in acute myocardial infarction in rats via modulation of the FGF21/CREB/PGC1α pathway.

Authors:  Yun-Jie Wei; Jun-Feng Wang; Fei Cheng; Hai-Jun Xu; Jia-Juan Chen; Jian Xiong; Jing Wang
Journal:  J Physiol Biochem       Date:  2021-06-19       Impact factor: 4.158

Review 9.  Noncoding RNAs as Biomarkers for Acute Coronary Syndrome.

Authors:  Lijie Wang; Yuanzhe Jin
Journal:  Biomed Res Int       Date:  2020-04-01       Impact factor: 3.411

10.  Diabetes Mellitus and Cardiovascular Risk Assessment in Mothers with a History of Gestational Diabetes Mellitus Based on Postpartal Expression Profile of MicroRNAs Associated with Diabetes Mellitus and Cardiovascular and Cerebrovascular Diseases.

Authors:  Ilona Hromadnikova; Katerina Kotlabova; Lenka Dvorakova; Ladislav Krofta
Journal:  Int J Mol Sci       Date:  2020-03-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.